Interferon and hormone sensitivity of endocrine-related tumors

Anti-Cancer Drugs

Volumn 7, Issue 2, 1996, Pages 150-160

  Sica, Gigliola ^a   Iacopino, Fortunata ^a   Recchia, Francesco ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b Civil Hospital   (Italy)

Author keywords

hormone; interferon; resistance; sensitivity

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA INTERFERON; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; HORMONE; HYDROXYFLUTAMIDE; INTERFERON; MEDROXYPROGESTERONE ACETATE; PROGESTERONE RECEPTOR; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ALPHA2C INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT GAMMA INTERFERON; STEROID RECEPTOR; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG MECHANISM; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; MALE; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 0030000719     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199602000-00002     Document Type: Review

References (80)

1. Borden EC. Interferons - expanding therapeutic roles. N Engl J Med 1992; 326: 1491-3.
2. Marth Ch, Mayer I, Bock G, et al. Effects of human Interferon alpha-2 and gamma on proliferation, estrogen receptor content, and sensitivity to anti-estrogens of cultured breast cancer cells. In: Dianzani F, Rossi GB, eds. The interferon system New York: Raven Press 1985: 367-71.
3. Iacobelli S, Natoli C, Anrò E, Sbarigia G, Gaggini C. An antiestrogenic action of interferons in human breast cancer cells. Anticancer Res. 1986; 6: 1391-4.
4. Sica G, Natoli V, Pellegrini A, Robustelli della Cuna G. The antiproliferative effect of tamoxifen and medroxy- progesterone acetate in breast cancer cells is potentiated by natural beta-interferon. In: Baulieu EE, Iacobelli S, McGuire WL, eds. Endocrinology and malignancy: basic and clinical issues. Carnforth, Parthenon Publishing 1986: 130-5.
5. van den Berg HW, Leahey WJ, Lynch M, Clarke R, Nelson J. Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitizes them to the anti-proliferative effects of tamoxifen. Br J Cancer 1987; 55 255-7.
6. Porzsolt F, Otto AM, Trauschel B, Buck C, Wawer AW, Schonenberger H. Rationale for combining tamoxifen and interferon in the treatment of advanced breast cancer. J Cancer Res Clin Oncol 1989; 115: 465-9.
7. Goldstein D, Bushmeyer SM, Win PL, Jordan VC, Borden EC. Effects of type I and II interferons on cultured human breast cancer cells: interaction with estrogen receptors and with tamoxifen. Cancer Res 1989; 49: 2698-702.
8. Solary E, Prud'Homme JF, Gauville C, Magdelenat H, Calvo F. Modulation of proliferation, estradiol receptors and estrogen regulated protein PS2/BCEI in human breast cancer cell lines by gamma interferon. J Biol Regul Homeost Agents 1991; 5/3: 98-106.
9. Sica G, Iacopino F, Robustelli della Cuna G, Marchetti P. Recombinant interferon-α2b affects proliferation, steroid receptors and sensitivity to tamoxifen of cultured breast cancer cells (CG-5). Anti-Cancer Drugs 1992; 3: 147-53.
10. Matsuo S, Takano S, Yamashita J, Ogawa M. Synergistic cytotoxic effects of tumor necrosis factor, interferon-γ and tamoxifen on breast cancer cell lines Anticancer Res 1992; 12: 1575-80.
11. Bezwoda WR, Meyer K. Effect of α-interferon, 17β-estradiol, and tamoxifen on estrogen receptor concentration and cell cycle kinetics of MCF-7 cells. Cancer Res 1990; 50: 5387-91.
12. Hakes T, Menendez-Botet C, Moore M, Osborne M. Modulation of estrogen (ER) and progesterone (PR) receptors in human breast cancer by alpha-2b interferon. Proc Am Soc Clin Oncol 1990; 9: 44.
13. Miglietta L, Repetto L, Gardin G, et al. Tamoxifen and alpha interferon in advanced breast cancer. J Chemother 1991; 3: 383-6.
14. Buzzi F, Brugia M, Rossi G, Giustini L, Scoponi C, Sica G. Combination of beta-interferon and tamoxifen as a new way to overcome clinical resistance to tamoxifen in advanced breast cancer. Anticancer Res 1992; 12: 869-72.
15. Cartei C, Marsilio P, Sibau A, et al. Usefulness of natural beta interferon added to tamoxifen in metastatic breast cancer in progression during T therapy. Proc 7th NCI- EORTC Symp on New Drugs in Cancer Therapy 1992: 170.
16. Seymour L, Bezwoda WR. Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators. Br J Cancer 1993; 68: 352-6.
17. Repetto L, Venturino A, Simoni C, Rosso M, Melioli G, Rosso R. Interferon in the treatment of advanced breast cancer. J Biol Regul Homeost Agents 1993; 7: 109-14.
18. Peretz T, Baider L, Catane R, et al. Interferon (IFN) and Tamoxifen (TAM) for patients with advanced breast cancer and negative estrogen receptors (ER). Eur J Cancer 1993; 29 (Suppl 6): S87.
19. Josui K, Kubota T, Kitajima. Recombinant human interferon-α2a increases hormone receptor level of a human breast carcinoma xenograft in nude mice and enhances the anti-proliferative activity of tamoxifen. Jpn J Cancer Res 1992; 83: 1347-53.
20. Gibson DFC, Johnson DA, Goldstein D, Langan-Fahey SM, Borden EC, Jordan VC. Human recombinant interferon-βser and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse. Breast Cancer Res Treat 1993; 25: 141-50.
21. Puillart P, Palangie T, Jouve M, et al. Administration of fibroblast interferon to patients with advanced breast cancer: possible effects on skin metastasis and on hormone receptors. Eur J Cancer Clin Oncol 1982; 18: 929-35.
22. Sica G, Natoli V, Stella C, Del Bianco S. Effect of natural beta-interferon on cell proliferation and steroid receptor level in human breast cancer cells. Cancer 1987; 60: 2419-23.
23. De Cicco F, Sica G, Benedetto MT, et al. In vitro effects of β-interferon on steroid receptors and prostaglandin output in human endometrial adenocarcinoma. J Steroid Biochem 1988; 30: 359-62
24. Sica G, Lama G, Tartaglione R, et al. Effects of natural beta-interferon and recombinant alpha-2b interferon on proliferation, glucocorticoid receptor content, and antigen expression in cultured HL-60 cells. Cancer 1990; 65: 920-5.
25. Angioli R, Untch M, Sevin BU, et al. Enhancement of progesterone receptor levels by interferons in AE-7 endometrial cancer cells. Cancer 1993; 71: 2776-81.
26. Sica G, Angelucci C, Iacopino F, et al. Effect of natural beta-interferon on estrogen receptor mRNA of breast cancer cells. Anticancer Res 1992; 12: 2061-4.
27. Epstein LB, Benz CC, Doty E. Synergistic antiproliferative effect of interferon-alpha and tamoxifen on human breast cancer cells in vitro. Clin Res 1987; 35: 196A.
28. Sica G, Iacopino F, Lama G, et al. Steroid receptor enhancement by natural beta-interferon in advanced breast cancer. Eur J Cancer 1993; 29: 329-33.
29. Sica G, Iacopino F, Lama G, et al. Natural interferon-β treatment and steroid hormone receptors in primary endometrial cancer. Gynecol Oncol 1993; 50: 185-90.
30. Scambia G, Benedetti Panici P, Battaglia F, et al. Effect of recombinant human interferon alpha2b on receptors for steroid hormones and epidermal growth factor in patients with endometrial cancer. Eur J Cancer 1991; 27: 51-3.
31. Kauppila A, Cantell K, Janne O, Kokko E, Vihko R. Serum sex steroid and peptide hormone concentrations, and endometrial estrogen and progestin receptor levels during administration of human leukocyte interferon. Int J Cancer 1982; 29: 291-4.
32. Marchetti P, Iacopino F, Lama G, et al. Effect of natural beta-interferon (β-IFN) on estrogen and progesterone receptors (ER, PR) in primary breast cancer (PBC). Br J Cancer (Suppl XII) 1990; 62: 25.
33. Young PCM, Ehrlich CE, Einhorn LH. Relationship between steroid receptors and response to endocrine therapy and cytotoxic chemotherapy in metastatic breast cancer. Cancer 1980; 46 (Suppl 12): 2961-3.
34. De Sombre ER. Breast cancer: hormone receptors, prognosis and therapy. In: Furr BJA, Saunders WB, eds. Clinical oncology. Philadelphia: Saunders 1982; 1: 191-213.
35. Kauppila AJI, Isotalo HE, Kivenen ST, Vihko RK. Prediction of clinical outcome with estrogen and progestin receptor concentrations and their relationships to clinical and histopathological variables in endometrial cancer. Cancer Res 1986; 46: 5380-4.
36. Martin JHJ, McKibben BM, Lynch M, van den Berg HW. Modulation by oestrogen and progestins/antiprogestins of alpha interferon receptor expression in human breast cancer cells. Eur J Cancer 1991; 27: 143-6.
37. Kerr DJ, Pragnell IB, Sproul A, et al. The cytostatic effects of α-interferon may be mediated by transforming growth factor β. J Mol Endocrinol 1989; 2: 131-6.
38. Knabbe C, Lippman ME, Wakefield LM, et al. Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417-28.
39. Chakravarthy A, Chen LC, Metha D, Hamburger AW. Modulation of epidermal growth factor receptors by gamma interferon in a human breast cancer cell line. Anticancer Res 1991; 11: 347-52.
40. Eisenkraft BL, Nanus DM, Albino AP, Pfeffer LM. α-interferon down-regulates epidermal growth factor receptors on renal carcinoma cells: relation to cellular responsiveness to the antiproliferative action of α-interferon. Cancer Res 1991; 51: 5881-7.
41. Zoon KC, Karasaki Y, zur Nedden DL, Hu R, Arnheiter H. Modulation of epidermal growth factor receptors by human α-interferon. Proc Natl Acad Sci USA 1986; 83: 8226-30.
42. Dotzlaw H, Miller T, Karvelas J, Murphy LC . Epidermal growth factor gene expression in human breast cancer biopsy samples: relationship to estrogen and progesterone receptor gene expression. Cancer Res 1990; 50: 4204-8.
43. Bolla M, Chedin M, Souvignet C, Marron J, Arnould C, Chambaz E. Estimation of epidermal growth factor receptor in 177 breast cancers: correlation with prognostic factors. Breast Cancer Res Treat 1990; 16: 97-102.
44. Nicholson S, Wright C, Sainsbury JRC, et al. Epidermal growth factor receptor (EGFr) as a market for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. J Steroid Biochem Mol Biol 1990; 37: 811-4.
45. Russell KS, Hung MC. Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res 1992; 52: 6624-9.
46. King CR, Borrello I, Bellot F, Comoglio P, Schlessinger J. EGF binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. EMBO J 1988; 7: 1647-51.
47. Mallmann P, Krebs D. Effect of tamoxifen on parameters of cell-mediated immunity in postmenopausal patients with breast carcinoma. Zentralbl Gynakol 1991; 113: 689-96.
48. Mandeville R, Chali SS, Chausseau JP. in vitro stimulation of human NK activity by an estrogen antagonist (tamoxifen). Eur J Cancer Clin Oncol 1984; 20: 983-5.
49. Brenner BG, Friedman G, Margolese RG. The relationship of clinical status and therapeutic modality to natural killer activity in human breast cancer. Cancer 1985; 56: 1543-48.
50. Lindner DJ, Kalvakolanu D, Mannino S, Borden EC. Tamoxifen enhances expression of interferon sensitive genes: protein kinase R and 2′5′ oligoadenynate synthetase. Proc Am Ass Cancer Res 1994; 35: 269.
51. Arteaga CL, Tandon AK, von Hoff DD, Osborne CK. Transforming growth factor β: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res 1988; 48: 3898-904.
52. Gastl G, Marth C, Leiter E, et al. Effect of human recombinant α2 arg-interferon and γ-interferon on human breast cancer cell lines: dissociation of antiproliferative activity and induction of HLA-DR antigen expression. Cancer Res 1985; 45: 2957-61.
53. Recchia F, Sica G, De Filippis S, et al. Interferon-β, retinoids and tamoxifen in the treatment of metastatic breast cancer: a phase II study. J Interferon Cytokine Res 1995; 15: 605-10.
54. Sporn MB, Roberts AB. Role of retinoids in differentiation and carcinogenesis. Cancer Res 1983; 43: 3034-40.
55. Marth C, Daxenbichler G, Dapunt O. Synergistic anti- proliferative effect of human recombinant interferons and retinoic acid in cultured breast cancer cells. J Natl Cancer Inst 1986; 77: 1197-202.
56. Kalvakolanu D, Mannino S, Lindner DJ, Borden EC. Synergistic modulation of IFN-stimulated gene expression by retinoic acid in embryonal carcinoma and breast tumor cells. Proc Am Ass Cancer Res 1994; 35: 310.
57. Lama G, Angelucci C, Recchia F, Sica G. Effect of 13-cis- retinoic acid and interferon β on proliferation of human breast cancer cells. Proc Am Ass Cancer Res 1994; 35: 88.
58. Barkley Butler W, Fontana JA. Responses to retinoic acid of tamoxifen-sensitive and -resistant sublines of human breast cancer cell line MCF-7. Cancer Res 1992; 52 6164-7.
59. Macheledt JE, Buzdar AU, Hortobagyi GN, Frye DK, Gutterman JU, Holmes FA. Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer. Breast Cancer Res Treat 1991; 18: 165-70.
60. Wildfang I, Grundel O, Schalke D, Bendel R, Kuhnle H, Schmoll HJ. A pilot study of r-alpha-interferon-2b (IFN) plus medroxyprogesterone acetate (MPA) in hormonal refractory metastatic breast cancer. Ann Oncol 1992; 3: (Suppl 5): 79.
61. Fedeli A, Cascinu S, Luzi Fedeli S, Catalano G. Beta- interferon (B-IFN) and medroxyprogesterone acetate (MAP) in advanced breast cancer (ABC) refractory to MAP. Ann Oncol 1992; 3(Suppl 5): 79.
62. Kaghn ME, Shankar Narayan K, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17: 16-23.
63. Sica G, Fabbroni L, Castagnetta L, Cacciatore M, Pavone- Macaluso M. Antiproliferative effect of interferons on human prostate carcinoma cell lines. Urol Res 1989; 17: 111-5.
64. Sica G, Dell'Acqua G, Iacopino F, et al. Androgen receptors and hormone sensitivity of a human prostatic cancer cell line (PC-3) are modulated by natural beta-interferon. Urol Res 1994; 22: 33-8.
65. Sica G, Iacopino F, Tommasi S, Primavera AT, Albarani V, De Lena M. Natural beta interferon affects c-myc mRNA expression in a human prostatic cancer cell line. J Interferon Res 1994; 14(Suppl 1): S163.
66. Okutani T, Nishi N, Kagawa Y, et al. Role of cyclic AMP and polypeptide growth regulators in growth inhibition by interferon in PC-3 cells. The Prostate 1991; 18: 73-80.
67. Pilkis SJ, Claus TH, Raafat El-Maghrabi M. The role of cyclic AMP in rapid and long-term regulation of gluconeogenesis and glycolysis. In: Greengard P, Robinson GA, eds. Advances in second messanger and phosphoprotein research. New York: Raven Press 1988; 22: 175-91.
68. Boynton AL, Whitfield JF. The role of cyclic AMP in cell proliferation: A critical assessment of the evidence: In: Greengard P, Robinson GA, eds. Advances in cyclic nucleotide research. New York: Raven Press 1983; 15: 193-294.
69. Lohmann SM, Walter U. Regulation of the cellular and subcellular concentrations and distribution of cyclic nucleotide-dependent protein kinases. In: Greengard P, Robinson GA, eds. Advances in cyclic nucleotide and protein phosphorylation research. New York: Raven Press 1984; 18: 63-117.
70. Cho-Chung YS. On the mechanism of cyclic AMP- mediated growth arrest of solid tumors. In: Hamet P, Sands H, eds. Advances in cyclic nucleotide research. New York, Raven Press 1980; 12: 111-21.
71. Puck TT. Genetic regulation of growth control: role of cyclic AMP and cell cytoskeleton. Somat Cell Mol Genet 1987; 12: 451-7.
72. Ashall F, Sullivan N, Puck TT. Specificity of the cAMP- induced gene exposure reaction in CHO cells. Proc Natl Acad Sci USA 1988; 85; 3908-12.
73. Bang YJ, Kim SJ, Danielpour D, et al. Cyclic AMP induces transforming growth factor β2 gene expression and growth arrest in the human androgen-independent prostate carcinoma cell line PC-3. Proc Natl Acad Sci USA 1992; 89: 3556-60.
74. Goldstein D, O'Leary M, Mitchen J, Borden EC, Wilding G. Effects of interferon βser and transforming growth factor β on prostatic cell lines. J Urol 1991; 146: 1173-7.
75. Blumenfeld W, Ye JQ, Dahiya R, Griffiss JM, Narayan P. HLA expression by benign and malignant prostatic epithelium : augmentation by interferon-gamma. J Urol 1993; 150: 1289-92.
76. Chang AYC, Fisher HAG, Spiers ASD, Boros L. Toxicities of human recombinant interferon-α2 in patients with advanced prostate carcinoma. J Interferon Res 1986; 6: 713-5.
77. Bulbul MA, Huben RP, Murphy GP. Interferon-β treatment of metastatic prostate cancer. J Surg Oncol 1986; 33: 231-3.
78. van Haelst-Pisani CM, Richardson RL, Su J, et al. A phase II study of recombinant alpha-interferon in advanced hormone-refractory prostate cancer. Cancer 1992; 70: 2310-2.
79. Voce S, Montanari F, Dal Pozzo C, et al. Immunoterapia adiuvante nel carcinoma della prostata ornomo-rsistente: risultati preliminari. In: Corrado F, Maltoni C, Corrado G, Ferri C, Palazzini A, Pinto C, eds. I Tumori Urologici: Recenti Progressi e Nuovi Obiettivi della Ricerca. Bologna: Monduzzi Editore 1992; II: 929-33.
80. Polledro P, Ambruoso G, Governa M, Fonnana G. Carcinoma prostatico in stadio localmente avanzato, svincolato dalla terapia ormonale: trattamento con interferon bata per via intralesionale. In: Corrado F Maltoni C, Corrado G, Ferri C, Palazzini A, Pinto C, eds. I Tunori Urologici: Recenti Progressi e Nuovi Obiettivi della Ricerca. Bologna: Monduzzi Editore 1992; II: 935-7.